Android app Apple app link

Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am

By Yahoo! Finance   |   1 month ago
Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am

Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies, rating Teva and Amneal as Buy and Viatris as Neutral. They highlighted improving fundamentals, strong cash flow, and undemanding valuations.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.